NCT02701400View on ClinicalTrials.gov

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

August 7, 2020

Study Completion Date

August 7, 2020

Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated radiation therapy

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Emory University

OTHER